Trial Profile
Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 16 Apr 2024 Status changed from active, no longer recruiting to completed.
- 20 Jun 2023 Planned End Date changed from 1 Jun 2023 to 29 Mar 2024.
- 20 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 29 Mar 2024.